Here is a helminth abstract from the AAN meeting, not sure if it has been posted already...
A Phase 1 Trial of Probiotic Helminth Ova in Relapsing Remitting Multiple Sclerosis (RRMS)
John Fleming, JangEun Lee, Christopher Luzzio, Michael Carrithers, Aaron Field, Zsuzsanna Fabry, Madison, WI
OBJECTIVE: To investigate the safety of probiotic helminth ova in subjects with RRMS.
BACKGROUND: The hygiene hypothesis has been advanced as a possible factor in the etiology and pathogenesis of allergic and autoimmune diseases, including multiple sclerosis. The hygiene hypothesis proposes that evolutionarily unnatural levels of high sanitation in developed countries may contribute to abnormal development and regulation of the immune system. In this regard, Summers and colleagues demonstrated that oral administration of non-pathogenic helminth Trichuris suis ova (TSO) was safe and effective in inflammatory bowel disease (Gastroenterology 2005;128:825-832).
DESIGN/METHODS: To study the effects of TSO more generally, in a second autoimmune disease, a pilot safety trial was conducted in five treatment-nave relapsing remitting multiple sclerosis (RRMS) subjects by means of oral administration of 2,500 ova every two weeks for three months. TSO production and administration were conducted under good manufacturing procedures, extensive microbiological sterility testing, university IRB approval, and an investigator IND from the US FDA.
RESULTS: Monitoring of clinical (EDSS, MSFC, relapses), gastrointestinal (symptom questionnaire, stool ova and parasite), neuroimaging (MRI), and immunological (T regulatory cells, cytokines) parameters did not identify any safety concerns in the five subjects during three months of TSO administration. Detailed results of MRI and immunological data will be reported.
CONCLUSIONS/RELEVANCE: The results of this exploratory study provide a preliminary indication of safety of TSO in RRMS. The findings justify further investigation of putative treatments based on the hygiene hypothesis in multiple sclerosis, including longer-term trials and study of the immunological mechanisms of TSO action. Supported by: National Multiple Sclerosis Society
http://www.abstracts2view.com/aan2009se ... 9L_P07.141